Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBS8(1V270) in Advanced Solid Tumours
NCT04855435Phase 1Recruiting
- Sponsor
- MonTa Biosciences
- Start
- Apr 2021
- Primary completion
- Mar 2027
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of MBS8 in solid tumor, cutaneous melanoma (CM) and Uveal melanoma (UM) (2 arms), sponsored by MonTa Biosciences. Primary endpoints: Adverse events at 42 days, Dose limiting toxicities at 23 days and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
MBS8
03
Conditions
solid tumorcutaneous melanoma (CM)Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT04855435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855435.